Search

Your search keyword '"Shepherd, F.A."' showing total 291 results
Start Over Author "Shepherd, F.A."
291 results on '"Shepherd, F.A."'

57. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

Author

Rizvi, N.A., Cho, B.C., Reinmuth, N., Lee, K.H., Luft, A., Ahn, M.J., Heuvel, M. van den, Cobo, M., Vicente, D., Smolin, A., Moiseyenko, V., Antonia, S.J., Moulec, S. Le, Robinet, G., Natale, R., Schneider, J., Shepherd, F.A., Geater, S.L., Garon, E.B., Kim, E.S., Goldberg, S.B., Nakagawa, K., Raja, R., Higgs, B.W., Boothman, A.M., Zhao, L., Scheuring, U., Stockman, P.K., Chand, V.K., Peters, S., Rizvi, N.A., Cho, B.C., Reinmuth, N., Lee, K.H., Luft, A., Ahn, M.J., Heuvel, M. van den, Cobo, M., Vicente, D., Smolin, A., Moiseyenko, V., Antonia, S.J., Moulec, S. Le, Robinet, G., Natale, R., Schneider, J., Shepherd, F.A., Geater, S.L., Garon, E.B., Kim, E.S., Goldberg, S.B., Nakagawa, K., Raja, R., Higgs, B.W., Boothman, A.M., Zhao, L., Scheuring, U., Stockman, P.K., Chand, V.K., and Peters, S.

Abstract

Contains fulltext : 225429.pdf (Publisher’s version ) (Open Access), IMPORTANCE: Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in combination with anti-cytotoxic T-lymphocyte-associated antigen 4 have shown clinical activity in patients with metastatic non-small cell lung cancer. OBJECTIVE: To compare durvalumab, with or without tremelimumab, with chemotherapy as a first-line treatment for patients with metastatic non-small cell lung cancer. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3 randomized clinical trial (MYSTIC) was conducted at 203 cancer treatment centers in 17 countries. Patients with treatment-naive, metastatic non-small cell lung cancer who had no sensitizing EGFR or ALK genetic alterations were randomized to receive treatment with durvalumab, durvalumab plus tremelimumab, or chemotherapy. Data were collected from July 21, 2015, to October 30, 2018. INTERVENTIONS: Patients were randomized (1:1:1) to receive treatment with durvalumab (20 mg/kg every 4 weeks), durvalumab (20 mg/kg every 4 weeks) plus tremelimumab (1 mg/kg every 4 weeks, up to 4 doses), or platinum-based doublet chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end points, assessed in patients with ≥25% of tumor cells expressing PD-L1, were overall survival (OS) for durvalumab vs chemotherapy, and OS and progression-free survival (PFS) for durvalumab plus tremelimumab vs chemotherapy. Analysis of blood tumor mutational burden (bTMB) was exploratory. RESULTS: Between July 21, 2015, and June 8, 2016, 1118 patients were randomized. Baseline demographic and disease characteristics were balanced between treatment groups. Among 488 patients with ≥25% of tumor cells expressing PD-L1, median OS was 16.3 months (95% CI, 12.2-20.8) with durvalumab vs 12.9 months (95% CI, 10.5-15.0) with chemotherapy (hazard ratio [HR], 0.76; 97.54% CI, 0.56-1.02; P = .04 [nonsignificant]). Median OS was 11.9 months (95% CI, 9.0-17.7) with durvalumab plus tremelimumab (HR vs chemotherapy, 0.85; 98.77% CI, 0.61-1.17

Published
2020

59. Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment

Author

Tse, B.C., primary, Said, B.I., additional, Fan, Z.J., additional, Hueniken, K., additional, Patel, D., additional, Gill, G., additional, Liang, M., additional, Razooqi, M., additional, Brown, M.C., additional, Sacher, A.G., additional, Bradbury, P.A., additional, Shepherd, F.A., additional, Leighl, N.B., additional, Xu, W., additional, Howell, D., additional, Liu, G., additional, and O’Kane, G., additional

Published
2020
Full Text
View/download PDF

60. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

Author

Tsuboi, M., primary, Wu, Y-L., additional, He, J., additional, John, T., additional, Grohe, C., additional, Majem, M., additional, Goldman, J.W., additional, Laktionov, K., additional, Kim, S-W., additional, Kato, T., additional, Vu, H.V., additional, Akewanlop, C., additional, Yu, C-J., additional, de Marinis, F., additional, Domine, M., additional, Shepherd, F.A., additional, Yan, C., additional, Atasoy, A., additional, and Herbst, R., additional

Published
2020
Full Text
View/download PDF

63. LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

Author

Tsuboi, M., primary, Wu, Y-L., additional, He, J., additional, John, T., additional, Grohe, C., additional, Majem, M., additional, Goldman, J.W., additional, Laktionov, K., additional, Kim, S-W., additional, Kato, T., additional, Vu, H.V., additional, Akewanlop, C., additional, Yu, C-J., additional, de Marinis, F., additional, Domine, M., additional, Shepherd, F.A., additional, Yan, C., additional, Atasoy, A., additional, and Herbst, R., additional

Published
2020
Full Text
View/download PDF

65. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Author

Wu, Y.-L., primary, Mok, T.S.K., additional, Han, J.-Y., additional, Ahn, M.-J., additional, Delmonte, A., additional, Ramalingam, S.S., additional, Kim, S.-W., additional, Shepherd, F.A., additional, Laskin, J., additional, He, Y., additional, Akamatsu, H., additional, Theelen, W.S.M.E., additional, Su, W.-C., additional, John, T., additional, Sebastian, M., additional, Mann, H., additional, Miranda, M., additional, Laus, G., additional, Rukazenkov, Y., additional, and Papadimitrakopoulou, V., additional

Published
2019
Full Text
View/download PDF

67. Somatic alteration burden involving non-cancer genes predicts prognosis in early-stage non-small cell lung cancer

Author

Wang, D., Pham, N.-A., Freeman, T.M., Raghavan, V., Navab, R., Chang, J., Zhu, C.-Q., Ly, D., Tong, J., Wouters, B.G., Pintilie, M., Moran, M.F., Liu, G., Shepherd, F.A., and Tsao, M.-S.

Abstract

The burden of somatic mutations and neoantigens has been associated with improved survival in cancer treated with immunotherapies, especially non-small cell lung cancer (NSCLC). However, there is uncertainty about their effect on outcome in early-stage untreated cases. We posited that the burden of mutations in a specific set of genes may also contribute to the prognosis of early NSCLC patients. From a small cohort of 36 NSCLC cases, we were able to identify somatic mutations and copy number alterations in 865 genes that contributed to patient overall survival. Simply, the number of altered genes (NAG) among these 865 genes was associated with longer disease-free survival (hazard ratio (HR) = 0.153, p = 1.48 × 10−4). The gene expression signature distinguishing patients with high/low NAG was also prognostic in three independent datasets. Patients with a high NAG could be further stratified based on the presence of immunogenic mutations, revealing a further subgroup of stage I NSCLC with even better prognosis (85% with >5 years survival), and associated with cytotoxic T-cell expression. Importantly, 95% of the highly-altered genes lacked direct relation to cancer, but were implicated in pathways regulating cell proliferation, motility and immune response.

Published
2019

68. Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Author

Reinmuth, N., primary, Cho, B.C., additional, Lee, K.H., additional, Luft, A., additional, Ahn, M.-J., additional, Schneider, J., additional, Shepherd, F.A., additional, Geater, S.L., additional, Pápai-Székely, Z., additional, Van Ngoc, T., additional, Garassino, M.C., additional, Liu, F., additional, Clemett, D., additional, Thiyagarajah, P., additional, Ouwens, M., additional, Scheuring, U., additional, Peters, S., additional, and Rizvi, N., additional

Published
2019
Full Text
View/download PDF

69. Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort

Author

Juergens, R.A., primary, Mariano, C., additional, Jolivet, J., additional, Finn, N., additional, Rothenstein, J., additional, Reaume, M.N., additional, Faghih, A., additional, Labbé, C., additional, Owen, S., additional, Shepherd, F.A., additional, Villeneuve, J., additional, Romeyer, F., additional, Pettersson, F., additional, and Butts, C., additional

Published
2018
Full Text
View/download PDF

71. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

Author

McKay, J.D., Hung, R.J., Han, Y., Zong, X., Carreras-Torres, R., Christiani, D.C., Caporaso, N., Johansson, M., Li, Y., Byun, J.Y., Dunning, A., Pooley, K.A., Qian, D.C., Liu, G., Bojesen, S.E., Wu, X., Marchand, L. le, Albanes, D., Bickeböller, H., Aldrich, M.C., Bush, W.S., Tardon, A., Rennert, G., Teare, M.D., Field, J.K., Kiemeney, L.A., Lazarus, P., Haugen, A., Schabath, M.B., Andrew, A.S., Shen, H., Hong, Y.C., Yuan, J.M., Bertazzi, P.A., Pesatori, A.C., Ye, Y., Diao, N., Su, L., Zhang, R., Brhane, Y., Leighl, N., Johansen, J.S., Mellemgaard, A., Saliba, W., Haiman, C.A., Wilkens, L.R., Fernandez-Somoano, A., Fernandez-Tardon, G., Heijden, H.F.M. van der, Kim, J.H., Hu, Z, Davies, M., Brunnström, H., Manjer, J., Melander, O., Muller, D., Overvad, K., Trichopoulou, A., Tumino, R., Doherty, J.A., Barnett, M.P., Chen, C., Goodman, G.E., Cox, A, Taylor, F., Woll, P.J., Brüske, I., Wichmann, H.E., Manz, J., Muley, T.R., Risch, A., Rosenberger, A., Grankvist, K., Shepherd, F.A., Tsao, M.S., Haura, E.B., Bolca, C., Holcatova, I., Janout, V., Kontic, M., Lissowska, J., Mukeria, A., Ognjanovic, S., Orlowski, T.M., Scelo, G., Swiatkowska, B., Zaridze, D., Bakke, P., Skaug, V., Zienolddiny, S., Duell, E.J., Butler, L.M., Koh, W.P., Gao, Y.T., Houlston, R.S., McLaughlin, J., Stevens, V.L., Joubert, P., Lamontagne, M., Nickle, D.C., Obeidat, M., Timens, W., Zhu, B, Kachuri, L., Artigas, M.S., Tobin, M.D., Wain, L.V., Rafnar, T., Thorgeirsson, T.E., Reginsson, G.W., Stefansson, K., Hancock, D.B., Bierut, L.J., Spitz, M.R., Gaddis, N.C., Lutz, S.M., Kamal, A., Pikielny, C., Zhu, D., Lindströem, S., Jiang, X., Tyndale, R.F., Chenevix-Trench, G., Beesley, J., Bossé, Y., Chanock, S., Brennan, P., Landi, M.T., Amos, C.I., McKay, J.D., Hung, R.J., Han, Y., Zong, X., Carreras-Torres, R., Christiani, D.C., Caporaso, N., Johansson, M., Li, Y., Byun, J.Y., Dunning, A., Pooley, K.A., Qian, D.C., Liu, G., Bojesen, S.E., Wu, X., Marchand, L. le, Albanes, D., Bickeböller, H., Aldrich, M.C., Bush, W.S., Tardon, A., Rennert, G., Teare, M.D., Field, J.K., Kiemeney, L.A., Lazarus, P., Haugen, A., Schabath, M.B., Andrew, A.S., Shen, H., Hong, Y.C., Yuan, J.M., Bertazzi, P.A., Pesatori, A.C., Ye, Y., Diao, N., Su, L., Zhang, R., Brhane, Y., Leighl, N., Johansen, J.S., Mellemgaard, A., Saliba, W., Haiman, C.A., Wilkens, L.R., Fernandez-Somoano, A., Fernandez-Tardon, G., Heijden, H.F.M. van der, Kim, J.H., Hu, Z, Davies, M., Brunnström, H., Manjer, J., Melander, O., Muller, D., Overvad, K., Trichopoulou, A., Tumino, R., Doherty, J.A., Barnett, M.P., Chen, C., Goodman, G.E., Cox, A, Taylor, F., Woll, P.J., Brüske, I., Wichmann, H.E., Manz, J., Muley, T.R., Risch, A., Rosenberger, A., Grankvist, K., Shepherd, F.A., Tsao, M.S., Haura, E.B., Bolca, C., Holcatova, I., Janout, V., Kontic, M., Lissowska, J., Mukeria, A., Ognjanovic, S., Orlowski, T.M., Scelo, G., Swiatkowska, B., Zaridze, D., Bakke, P., Skaug, V., Zienolddiny, S., Duell, E.J., Butler, L.M., Koh, W.P., Gao, Y.T., Houlston, R.S., McLaughlin, J., Stevens, V.L., Joubert, P., Lamontagne, M., Nickle, D.C., Obeidat, M., Timens, W., Zhu, B, Kachuri, L., Artigas, M.S., Tobin, M.D., Wain, L.V., Rafnar, T., Thorgeirsson, T.E., Reginsson, G.W., Stefansson, K., Hancock, D.B., Bierut, L.J., Spitz, M.R., Gaddis, N.C., Lutz, S.M., Kamal, A., Pikielny, C., Zhu, D., Lindströem, S., Jiang, X., Tyndale, R.F., Chenevix-Trench, G., Beesley, J., Bossé, Y., Chanock, S., Brennan, P., Landi, M.T., and Amos, C.I.

Abstract

Contains fulltext : 177377.pdf (Publisher’s version ) (Closed access)

Published
2017

72. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)

Author

Peters, S., Gettinger, S., Johnson, M.L., Janne, P.A., Garassino, M.C., Christoph, D., Toh, C.K., Rizvi, N.A., Chaft, J.E., Costa, E., Patel, J.D., Chow, L.Q.M., Koczywas, M., Ho, C., Fruh, M., Heuvel, M. van den, Rothenstein, J., Reck, M., Paz-Ares, L., Shepherd, F.A., Kurata, T., Li, Z., Qiu, J., Kowanetz, M., Mocci, S., Shankar, G., Sandler, A., Felip, E., Peters, S., Gettinger, S., Johnson, M.L., Janne, P.A., Garassino, M.C., Christoph, D., Toh, C.K., Rizvi, N.A., Chaft, J.E., Costa, E., Patel, J.D., Chow, L.Q.M., Koczywas, M., Ho, C., Fruh, M., Heuvel, M. van den, Rothenstein, J., Reck, M., Paz-Ares, L., Shepherd, F.A., Kurata, T., Li, Z., Qiu, J., Kowanetz, M., Mocci, S., Shankar, G., Sandler, A., and Felip, E.

Abstract

Item does not contain fulltext, Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non-small-cell lung cancer (NSCLC) across lines of therapy. Patients were selected on the basis of PD-L1 expression on tumor cells (TC) or tumor-infiltrating immune cells (IC). Patients and Methods Eligible patients had advanced-stage NSCLC, no CNS metastases, and zero to two or more lines of prior chemotherapy. Patients whose tumors expressed PD-L1 using the SP142 immunohistochemistry assay on >/= 5% of TC or IC (TC2/3 or IC2/3 [TC or IC >/= 5% PD-L1-expressing cells, respectively]) were enrolled. Atezolizumab 1,200 mg was administered intravenously every 3 weeks. Efficacy-evaluable patients (N = 659) comprised three cohorts: first line (cohort 1; n = 139); second line (cohort 2; n = 268); and third line or higher (cohort 3; n = 252). The primary end point was independent review facility-assessed objective response rate (ORR; Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1). Secondary end points included median duration of response, progression-free survival, and overall survival (OS). Results BIRCH met its primary objective of demonstrating a significant ORR versus historical controls. With a minimum of 12 months of follow-up, the independent review facility-assessed ORR was 18% to 22% for the three cohorts, and 26% to 31% for the TC3 or IC3 subgroup; most responses are ongoing. Responses occurred regardless of EGFR or KRAS mutation status. The median OS from an updated survival analysis (minimum of 20 month follow up) for cohort 1 was 23.5 months (26.9 months for TC3 or IC3 patients); the median OS in cohorts 2 and 3 was 15.5 and 13.2 months, respectively. The safety profile was similar across cohorts and consistent with previous atezolizumab monotherapy trials. Conclusion BIRCH demonstrated responses with atezolizumab monotherapy in patients with PD-L1-selected advanced NSCLC, with good tolerabi

Published
2017

73. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors

Author

Wang, D., Pham, N.-A., Tong, J., Sakashita, S., Allo, G., Kim, L., Yanagawa, N., Raghavan, V., Wei, Y., To, C., Trinh, Q.M., Starmans, M.H.W., Chan-Seng-Yue, M.A., Chadwick, D., Li, L., Zhu, C.-Q., Liu, N., Li, M., Lee, S., Ignatchenko, V., Strumpf, D., Taylor, P., Moghal, N., Liu, G., Boutros, P.C., Kislinger, T., Pintilie, M., Jurisica, I., Shepherd, F.A., McPherson, J.D., Muthuswamy, L., Moran, M.F., and Tsao, M.-S.

Subjects
Adult, Male, Lung Neoplasms, Mice, SCID, Middle Aged, Polymorphism, Single Nucleotide, Xenograft Model Antitumor Assays, Disease Models, Animal, Mice, Mice, Inbred NOD, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Mutation, Animals, Heterografts, Humans, Female, Aged
Abstract

Availability of lung cancer models that closely mimic human tumors remains a significant gap in cancer research, as tumor cell lines and mouse models may not recapitulate the spectrum of lung cancer heterogeneity seen in patients. We aimed to establish a patient-derived tumor xenograft (PDX) resource from surgically resected non-small cell lung cancer (NSCLC). Fresh tumor tissue from surgical resection was implanted and grown in the subcutaneous pocket of non-obese severe combined immune deficient (NOD SCID) gamma mice. Subsequent passages were in NOD SCID mice. A subset of matched patient and PDX tumors and non-neoplastic lung tissues were profiled by whole exome sequencing, single nucleotide polymorphism (SNP) and methylation arrays, and phosphotyrosine (pY)-proteome by mass spectrometry. The data were compared to published NSCLC datasets of NSCLC primary and cell lines. 127 stable PDXs were established from 441 lung carcinomas representing all major histological subtypes: 52 adenocarcinomas, 62 squamous cell carcinomas, one adeno-squamous carcinoma, five sarcomatoid carcinomas, five large cell neuroendocrine carcinomas, and two small cell lung cancers. Somatic mutations, gene copy number and expression profiles, and pY-proteome landscape of 36 PDXs showed greater similarity with patient tumors than with established cell lines. Novel somatic mutations on cancer associated genes were identified but only in PDXs, likely due to selective clonal growth in the PDXs that allows detection of these low allelic frequency mutations. The results provide the strongest evidence yet that PDXs established from lung cancers closely mimic the characteristics of patient primary tumors.

Published
2016

74. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Author

Wu, Y.-L., Mok, T.S.K., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S.S., Kim, S.-W., Shepherd, F.A., Laskin, J., He, Y., Akamatsu, H., Theelen, W.S.M.E., Su, W.-C., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., and Papadimitrakopoulou, V.

Published
2019
Full Text
View/download PDF

75. Outcomes for Cervical Mediastinoscopy in a Community Teaching Hospital

Author

Dahele, M., Ung, Y., Bezjak, A., Burkes, R., Ellis, P., Behzadi, A., Solow, H., Laffan, S., Korec, M., Pearson, S., Purdie, T., Bissonnette, J.P., Brade, A., Cho, J.B.C., Sun, A., Hope, A., Franks, K., Jaffray, D.A., Lee, J., Correia, J.D., Walele, A.A., Ashrafi, A.S., Sturdza, A., Payne, D., Kane, G., Hodgson, D., Waldron, J., Catapano, J., Shepherd, F.A., Keshavjee, S., Anraku, M., Yun, Z., Zhang, L., Johnston, M.R., de Perrot, M., Louie, A., Rodrigues, G., Whiston, F., Stitt, L., Mathew, L., Parraga, G., Para, A.E., Calveley, V.L., Yeung, I.W.T., Van Dyk, J., Hill, R.P., Pan, L., Cohen, J., Okawara, G., Nair, P., Soliman, H., Cheung, P., Poon, I., Balogh, J., Barbera, L., Spayne, J., Danjoux, C., Lim, G., Higgins, J., Moseley, D., Hope, D., Cho, J., and Le, L.

Subjects
Ontario, Abstracts, lung cancer, Meeting Report and Abstracts, Thoracic cancer, conference
Published
2008

76. Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26

Author

Karim, S., primary, Ding, K., additional, Bradbury, P., additional, Ellis, P., additional, Mittman, N., additional, Xiaoqun Sun, X., additional, Millward, M., additional, Liu, G., additional, Sun, S., additional, Stockler, M.R., additional, Cohen, V., additional, Blais, N., additional, Sangha, R., additional, Boyer, M., additional, Sasidharan, R., additional, Lee, C., additional, Shepherd, F.A., additional, Goss, G., additional, Seymour, L., additional, and Leighl, N.B., additional

Published
2017
Full Text
View/download PDF

78. Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)

Author

Reck, M., primary, Paz-Ares, L., additional, Moro-Sibilot, D., additional, Shepherd, F.A., additional, Cappuzzo, F., additional, Winfree, K.B., additional, Alexandris, E., additional, Sashegyi, A., additional, Varea, R., additional, and Pérol, M., additional

Published
2017
Full Text
View/download PDF

79. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

Author

Gettinger, S.N., primary, Hellmann, M.D., additional, Shepherd, F.A., additional, Antonia, S.J., additional, Brahmer, J., additional, Chow, L.Q., additional, Goldman, J., additional, Juergens, R., additional, Borghaei, H., additional, Ready, N.E., additional, Gerber, D.E., additional, Nathan, F., additional, Shen, Y., additional, Harbison, C.T., additional, and Rizvi, N., additional

Published
2015
Full Text
View/download PDF

80. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies

Author

Goss, G.D., primary, Yang, J.C.H., additional, Ahn, M.J., additional, Tsai, C.M., additional, Bazhenova, L., additional, Sequist, L.V., additional, Ramalingam, S.S., additional, Shepherd, F.A., additional, Ghiorghiu, S., additional, Cantarini, M., additional, Mann, H., additional, Mitsudomi, T., additional, and Jänne, P.A., additional

Published
2015
Full Text
View/download PDF

81. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

Author

Ahn, M.J., primary, Tsai, C.M., additional, Yang, J.C.H., additional, Shepherd, F.A., additional, Satouchi, M., additional, Kim, D.W., additional, Bazhenova, L., additional, Hirashima, T., additional, Rukazenkov, Y., additional, Cantarini, M., additional, Mann, H., additional, Ramalingam, S.S., additional, Mitsudomi, T., additional, Jänne, P.A., additional, and Goss, G.D., additional

Published
2015
Full Text
View/download PDF

83. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

Author

Mitchell, P., primary, Thatcher, N., additional, Socinski, M.A., additional, Wasilewska-Tesluk, E., additional, Horwood, K., additional, Szczesna, A., additional, Martín, C., additional, Ragulin, Y., additional, Zukin, M., additional, Helwig, C., additional, Falk, M., additional, Butts, C., additional, and Shepherd, F.A., additional

Published
2015
Full Text
View/download PDF

84. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Author

Scagliotti, G.V., primary, Bondarenko, I., additional, Blackhall, F., additional, Barlesi, F., additional, Hsia, T.-C., additional, Jassem, J., additional, Milanowski, J., additional, Popat, S., additional, Sanchez-Torres, J.M., additional, Novello, S., additional, Benner, R.J., additional, Green, S., additional, Molpus, K., additional, Soria, J.-C., additional, and Shepherd, F.A., additional

Published
2015
Full Text
View/download PDF

85. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Author

Antonia, S.J., primary, Brahmer, J.R., additional, Gettinger, S., additional, Chow, L.Q., additional, Juergens, R., additional, Shepherd, F.A., additional, Laurie, S.A., additional, Gerber, D.E., additional, Goldman, J., additional, Shen, Y., additional, Harbison, C., additional, Chen, A.C., additional, Borghaei, H., additional, and Rizvi, N.A., additional

Published
2014
Full Text
View/download PDF

88. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

Author

Rizvi, N.A., primary, Shepherd, F.A., additional, Antonia, S.J., additional, Brahmer, J.R., additional, Chow, L.Q., additional, Goldman, J., additional, Juergens, R., additional, Borghaei, H., additional, Ready, N.E., additional, Gerber, D.E., additional, Shen, Y., additional, Harbison, C., additional, Chen, A.C., additional, and Gettinger, S., additional

Published
2014
Full Text
View/download PDF

93. Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc)

Author

Gettinger, S., primary, Rizvi, N., additional, Chow, L.Q., additional, Borghaei, H., additional, Brahmer, J.R., additional, Juergens, R., additional, Shepherd, F.A., additional, Laurie, S.A., additional, Gerber, D.E., additional, Goldman, J., additional, Shen, Y., additional, Harbison, C., additional, Chen, A., additional, and Antonia, S.J., additional

Published
2014
Full Text
View/download PDF

97. Common and Rare Egfr Mutations (Egfrm) in the Radiant Trial

Author

Eberhardt, W.E.E., primary, Shepherd, F.A., additional, Altorki, N.K., additional, O'Brien, M.E.R., additional, Wang, J., additional, Wu, J., additional, Gill, S.C., additional, Iwata, K.K., additional, Richardson, F.C., additional, Horan, J.D., additional, Foley, M.A., additional, and Kelly, K., additional

Published
2014
Full Text
View/download PDF

98. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

Author

Laurie, S.A., primary, Solomon, B.J., additional, Seymour, L., additional, Ellis, P.M., additional, Goss, G.D., additional, Shepherd, F.A., additional, Boyer, M.J., additional, Arnold, A.M., additional, Clingan, P., additional, Laberge, F., additional, Fenton, D., additional, Hirsh, V., additional, Zukin, M., additional, Stockler, M.R., additional, Lee, C.W., additional, Chen, E.X., additional, Montenegro, A., additional, Ding, K., additional, and Bradbury, P.A., additional

Published
2014
Full Text
View/download PDF

99. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Author

Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L., Li, L.Y., Watkins, C.L., Sellers, M.V., Lowe, E.S., Sun, Y., Liao, M.L., Reck, M., Armour, A.A., Shepherd, F.A., Lippman, S.M., Douillard, J.Y., Østerlind, Kell, Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L., Li, L.Y., Watkins, C.L., Sellers, M.V., Lowe, E.S., Sun, Y., Liao, M.L., Reck, M., Armour, A.A., Shepherd, F.A., Lippman, S.M., Douillard, J.Y., and Østerlind, Kell

Abstract

BACKGROUND: Two phase II trials in patients with previously-treated advanced non-small-cell lung cancer suggested that gefitinib was efficacious and less toxic than was chemotherapy. We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy. METHODS: We undertook an open-label phase III study with recruitment between March 1, 2004, and Feb 17, 2006, at 149 centres in 24 countries. 1466 patients with pretreated (>/=one platinum-based regimen) advanced non-small-cell lung cancer were randomly assigned with dynamic balancing to receive gefitinib (250 mg per day orally; n=733) or docetaxel (75 mg/m(2) intravenously in 1-h infusion every 3 weeks; n=733). The primary objective was to compare overall survival between the groups with co-primary analyses to assess non-inferiority in the overall per-protocol population and superiority in patients with high epidermal growth factor receptor (EGFR)-gene-copy number in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00076388. FINDINGS: 1433 patients were analysed per protocol (723 in gefitinib group and 710 in docetaxel group). Non-inferiority of gefitinib compared with docetaxel was confirmed for overall survival (593 vs 576 events; hazard ratio [HR] 1.020, 96% CI 0.905-1.150, meeting the predefined non-inferiority criterion; median survival 7.6 vs 8.0 months). Superiority of gefitinib in patients with high EGFR-gene-copy number (85 vs 89 patients) was not proven (72 vs 71 events; HR 1.09, 95% CI 0.78-1.51; p=0.62; median survival 8.4 vs 7.5 months). In the gefitinib group, the most common adverse events were rash or acne (360 [49%] vs 73 [10%]) and diarrhoea (255 [35%] vs 177 [25%]); whereas in the docetaxel group, neutropenia (35 [5%] vs 514 [74%]), asthenic disorders (182 [25%] vs 334 [47%]), and alopecia (23 [3%] vs 254 [36%]) were most common. INTERPRETATION: INTERE

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results